Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid a in mice

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Kamphuis, Tobias ^a   Meijerhof, Tjarko ^a   Stegmann, Toon ^a,b   Lederhofer, Julia ^a   Wilschut, Jan ^a   de Haan, Aalzen ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Mymetics BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 5; RESPIRATORY SYNCYTIAL VIRUS MONOPHOSPHORYL LIPID A VIROSOMAL VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIROSOME; VIROSOME VACCINE; VIRUS VACCINE; DRUG DERIVATIVE; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INTERLEUKIN 2; LIPID A; PHOSPHORYL LIPID A; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LUNG; MOUSE; NONHUMAN; PHENOTYPE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SPLEEN; TH1 CELL; VACCINATION; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ANIMALIA; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-2; LIPID A; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SPLEEN; TH1 CELLS; VACCINES, INACTIVATED; VACCINES, VIROSOME;

EID: 84860764098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036812     Document Type: Article

References (45)

1. van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J, (2007) Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17: 5-34 doi:10.1002/rmv.518.
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, et al. (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375: 1545-1555 doi:10.1016/S0140-6736(10)60206-1.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
4. Falsey AR, Walsh EE, (2006) Viral pneumonia in older adults. Clin Infect Dis 42: 518-524 doi:10.1086/499955.
5. Groothuis JR, Hoopes JM, Hemming VG, (2011) Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 28: 110-125 doi:10.1007/s12325-010-0101-y.
6. Hampp C, Kauf TL, Saidi AS, Winterstein AG, (2011) Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications. Arch Pediatr Adolesc Med doi:10.1001/archpediatrics.2010.298.
7. Polack FP, Karron RA, (2004) The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 23: S65-73 doi:10.1097/01.inf.0000108194.71892.95.
8. Falsey AR, (2007) Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 28: 171-181 doi:10.1055/s-2007-976489.
9. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE, (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89: 405-421.
10. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH, (1969) Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89: 449-463.
11. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, et al. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434.
12. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, et al. (1969) Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89: 435-448.
13. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, et al. (1986) Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24: 197-202.
14. Murphy BR, Walsh EE, (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26: 1595-1597.
15. KIM H, CANCHOLA J, (1969) Respiratory syncytial virus disease in infants despite prior administra- tion of antigenic inactivated vaccine. American Journal of.
16. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, et al. (1993) Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151: 2032-2040.
17. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, et al. (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15: 34-41 doi:10.1038/nm.1894.
18. Guy B, (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5: 505-517 doi:10.1038/nrmicro1681.
19. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, et al. (2001) Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2: 947-950 doi:10.1038/ni712.
20. Netea MG, Van der Meer JWM, Sutmuller RP, Adema GJ, Kullberg B-J, (2005) From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias. Antimicrobial Agents and Chemotherapy 49: 3991 doi:10.1128/AAC.49.10.3991-3996.2005.
21. Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, et al. (2010) Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine 28: 5543-5550 doi:10.1016/j.vaccine.2010.06.041.
22. Casella CR, Mitchell TC, (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65: 3231-3240 doi:10.1007/s00018-008-8228-6.
23. Johnson RS, Her GR, Grabarek J, Hawiger J, Reinhold VN, (1990) Structural characterization of monophosphoryl lipid A homologs obtained from Salmonella minnesota Re595 lipopolysaccharide. J Biol Chem 265: 8108-8116.
24. Crommelin D, Stolk P, Besançon L, Shah V, Midha K, et al. (2010) Pharmaceutical sciences in 2020. Nat Rev Drug Discov 9: 99-100 doi:10.1038/nrd3087.
25. Akira S, Takeda K, (2004) Toll-like receptor signalling. Nat Rev Immunol 4: 499-511 doi:10.1038/nri1391.
26. Garçon N, Segal L, Tavares F, van Mechelen M, (2011) The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 29: 4453-4459 doi:10.1016/j.vaccine.2011.04.046.
27. Guy B, (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5: 505-517 doi:10.1038/nrmicro1681.
28. Garçon N, Wettendorff M, van Mechelen M, (2011) Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 11: 667-677 doi:10.1517/14712598.2011.573624.
29. Duthie MS, Windish HP, Fox CB, Reed SG, (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239: 178-196 doi:10.1111/j.1600-065X.2010.00978.x.
30. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, et al. (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183: 6186-6197 doi:10.4049/jimmunol.0901474.
31. Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, et al. (2006) The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 24: 5027-5035 doi:10.1016/j.vaccine.2006.03.064.
32. Prince GA, Denamur F, Deschamps M, Garçon N, Prieels JP, et al. (2001) Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19: 2048-2054.
33. Budimir N, Meijerhof T, Wilschut J, Huckriede A, de Haan A, (2010) The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes. Vaccine 28: 8280-8287 doi:10.1016/j.vaccine.2010.10.007.
34. Prince GA, Curtis SJ, Yim KC, Porter DD, (2001) Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82: 2881-2888.
35. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, et al. (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1: 398-401 doi:10.1038/80833.
36. Graham BS, (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239: 149-166 doi:10.1111/j.1600-065X.2010.00972.x.
37. Welliver RC, Kaul TN, Sun M, Ogra PL, (1984) Defective regulation of immune responses in respiratory syncytial virus infection. J Immunol 133: 1925-1930.
38. Welliver RC, Wong DT, Sun M, Middleton E, Vaughan RS, et al. (1981) The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med 305: 841-846 doi:10.1056/NEJM198110083051501.
39. Becker Y, (2006) Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes 33: 235-252 doi:10.1007/s11262-006-0064-x.
40. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, et al. (2010) Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med 207: 1485-1500 doi:10.1084/jem.20092695.
41. Nimmerjahn F, Ravetch JV, (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512 doi:10.1126/science.1118948.
42. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J, (1987) IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 165: 64-69.
43. Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, et al. (2007) TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 178: 2182-2191.
44. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, et al. (2006) A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12: 905-907 doi:10.1038/nm1456.
45. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, et al. (2010) Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 17: 248-250 doi:10.1038/nsmb.1723.